Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

February 05, 2018 17:04 ET | Source: Calithera Biosciences, Inc.

Results from Phase I Study of CB-839 in Combination with Everolimus or Cabozantinib in Patients with Renal Cell Carcinoma to be Presented at the 2018 American Society of Clinical Oncology Genitourinary Cancer Symposium

-Overall response rate of 40% and 100% disease control rate in advanced clear cell renal cell carcinoma patients treated with CB-839 plus Cabozantinib -Randomized placebo controlled CANTATA Phase 2...
December 05, 2017 08:00 ET | Source: Calithera Biosciences, Inc.

Updated Results from Phase I Study of CB-839 in Combination with Paclitaxel in Patients with Triple Negative Breast Cancer to be Presented at the 2017 San Antonio Breast Cancer Symposium

SOUTH SAN FRANCISCO, Calif., Dec. 05, 2017 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq:CALA), a clinical stage biotechnology company focused on discovering and developing novel small...
November 07, 2017 08:01 ET | Source: Calithera Biosciences, Inc.

Initial Results from Phase 2 Study of CB-839 in Combination with Opdivo® (nivolumab) to be Presented at the Society for Immunotherapy of Cancer Meeting

Achieved confirmed responses in melanoma patients progressing on PD-1/PD-L1 therapy Expanding Bristol-Myers Squibb clinical collaboration SOUTH SAN FRANCISCO, Calif., Nov. 07, 2017 (GLOBE...
November 02, 2017 07:30 ET | Source: Calithera Biosciences, Inc.

Calithera Biosciences Reports Third Quarter 2017 Financial Results and Recent Highlights

SOUTH SAN FRANCISCO, Calif., Nov. 02, 2017 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq:CALA), a clinical-stage pharmaceutical company focused on discovering and developing novel small...
October 19, 2017 08:00 ET | Source: Calithera Biosciences, Inc.

Calithera Announces First Patient Treated in Phase 1 Cohort of INCB01158 dosed in Combination with Keytruda

SOUTH SAN FRANCISCO, Calif., Oct. 19, 2017 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq:CALA), a clinical-stage pharmaceutical company focused on discovering and developing novel small...
October 03, 2017 08:00 ET | Source: Calithera Biosciences, Inc.

Calithera Biosciences Announces Appointment of Sumita Ray as General Counsel

SOUTH SAN FRANCISCO, Calif., Oct. 03, 2017 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq:CALA), a clinical-stage pharmaceutical company focused on discovering and developing novel small...
September 21, 2017 16:05 ET | Source: Calithera Biosciences, Inc.

Calithera Biosciences Appoints Blake Wise to Board of Directors

SOUTH SAN FRANCISCO, Calif., Sept. 21, 2017 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq:CALA), a clinical-stage pharmaceutical company focused on discovering and developing novel small...
September 20, 2017 08:00 ET | Source: Calithera Biosciences, Inc.

Calithera Biosciences to Present at the 2017 Cantor Fitzgerald Global Healthcare Conference and the Leerink Partners Immuno-Oncology Roundtable

SOUTH SAN FRANCISCO, Calif., Sept. 20, 2017 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq:CALA), a clinical-stage pharmaceutical company focused on discovering and developing novel small...
September 19, 2017 15:11 ET | Source: Calithera Biosciences, Inc.

Calithera Biosciences Announces CB-839 in Combination with Nivolumab Phase 1/2 Data Accepted for Oral Presentation at the Society for Immunotherapy of Cancer (SITC) 32nd Annual Meeting

SOUTH SAN FRANCISCO, Calif., Sept. 19, 2017 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq:CALA), a clinical-stage pharmaceutical company focused on discovering and developing novel small...
August 30, 2017 08:00 ET | Source: Calithera Biosciences, Inc.

Calithera Biosciences to Participate in the Citi 12th Annual Biotech Conference and the Wells Fargo Healthcare Conference

SOUTH SAN FRANCISCO, Calif., Aug. 30, 2017 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq:CALA), a clinical-stage pharmaceutical company focused on discovering and developing novel small...